Literature DB >> 17204720

Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen.

Hilmar Kuehl1, Patrick Veit, Sandra J Rosenbaum, Andreas Bockisch, Gerald Antoch.   

Abstract

Stage-adapted treatment in oncology relies on correct tumor staging for patients with malignant diseases. To ensure accurate assessment of the tumor stage in thoracic and abdominal diseases by PET/CT, both CT and PET need to be optimized. In this setting, different malignant diseases require customized imaging protocols. Although in the clinical setting of therapy assessment, PET/CT with integration of low-dose, nonenhanced CT may be sufficient, tumor staging may require a more sophisticated CT protocol. This review focuses on potential CT protocols for imaging cancers of the chest and abdomen. Examples of CT protocols are presented and discussed for non-small cell lung cancer, breast cancer, colorectal cancer, gastrointestinal stromal tumors, and interventional liver therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17204720

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  Hybrid versus fusion imaging: are we moving forward judiciously?

Authors:  Luca Giovanella; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05       Impact factor: 9.236

2.  What are the Best Ways to Reduce the False-positive Rate of 18F-FDG PET/CT in Patients with Breast Cancer?

Authors:  Laura Evangelista; Zora Baretta; Lorenzo Vinante; Guido Sotti
Journal:  Nucl Med Mol Imaging       Date:  2011-01-05

Review 3.  [PET/CT for diagnostics and therapy stratification of lung cancer].

Authors:  C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

4.  The current role of PET-CT in the characterization of hepatobiliary malignancies.

Authors:  Ginseppe Garcea; Seok Ling Ong; Guy J Maddern
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

Review 5.  Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies.

Authors:  Long Sun; Hua Wu; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

6.  Prevalence of clinically significant extraosseous findings on unenhanced CT portions of ¹⁸F-fluoride PET/CT bone scans.

Authors:  Chao-Jung Chen; Shih-Ya Ma
Journal:  ScientificWorldJournal       Date:  2012-09-10

Review 7.  PET/CT imaging: what radiologists need to know.

Authors:  M Benamor; L Ollivier; H Brisse; G Moulin-Romsee; V Servois; S Neuenschwander
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

8.  Assessment of myocardial extracellular volume on body computed tomography in breast cancer patients treated with anthracyclines.

Authors:  Caterina Beatrice Monti; Moreno Zanardo; Tommaso Bosetti; Marco Alì; Elena De Benedictis; Alberto Luporini; Francesco Secchi; Francesco Sardanelli
Journal:  Quant Imaging Med Surg       Date:  2020-05

9.  Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.

Authors:  Gonca G Bural; Ashok Muthukrishnan; Matthew J Oborski; James M Mountz
Journal:  Mol Imaging Radionucl Ther       Date:  2012-12-20

Review 10.  Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).

Authors:  Evelina Miele; Gian Paolo Spinelli; Federica Tomao; Angelo Zullo; Filippo De Marinis; Giulia Pasciuti; Luigi Rossi; Federica Zoratto; Silverio Tomao
Journal:  J Exp Clin Cancer Res       Date:  2008-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.